RU2302877C2 - Biological food supplement for treatment and prophylaxis of intestine infections complicated with dysbacteriosis and for enhancing nonspecific resistance of organism - Google Patents
Biological food supplement for treatment and prophylaxis of intestine infections complicated with dysbacteriosis and for enhancing nonspecific resistance of organism Download PDFInfo
- Publication number
- RU2302877C2 RU2302877C2 RU2005117480/13A RU2005117480A RU2302877C2 RU 2302877 C2 RU2302877 C2 RU 2302877C2 RU 2005117480/13 A RU2005117480/13 A RU 2005117480/13A RU 2005117480 A RU2005117480 A RU 2005117480A RU 2302877 C2 RU2302877 C2 RU 2302877C2
- Authority
- RU
- Russia
- Prior art keywords
- strain
- supplement
- lactobacillus rhamnosus
- treatment
- food supplement
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 6
- 208000027244 Dysbiosis Diseases 0.000 title claims description 9
- 230000007140 dysbiosis Effects 0.000 title claims description 9
- 238000011282 treatment Methods 0.000 title claims description 6
- 208000036649 Dysbacteriosis Diseases 0.000 title description 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 210000000936 intestine Anatomy 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 6
- 239000005018 casein Substances 0.000 claims abstract description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000021240 caseins Nutrition 0.000 claims abstract description 5
- 235000015097 nutrients Nutrition 0.000 claims abstract description 5
- 239000008213 purified water Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000002028 Biomass Substances 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 239000013589 supplement Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 241000186660 Lactobacillus Species 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- -1 bifidumbacterin Proteins 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- WOLQREOUPKZMEX-BZSNNMDCSA-N (2s)-2-[[(4s)-4-[[(4s)-4-[[4-[(2-amino-4-oxo-1h-pteridin-6-yl)methylamino]benzoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-BZSNNMDCSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 108010081391 Ristocetin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 108010041940 bifikol Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 108010038854 colibacterin Proteins 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 108010006741 lactobacterin Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003032 phytopathogenic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Изобретение относится к области биотехнологии, в частности к бактериальным препаратам для медицины, сельского хозяйства и пищевой промышленности, и касается средства, воздействующего на заболевания желудочно-кишечного тракта.The invention relates to the field of biotechnology, in particular to bacterial preparations for medicine, agriculture and the food industry, and relates to a drug that affects the diseases of the gastrointestinal tract.
Широко известны препараты, направленные на восстановление нормального биоценоза кишечника, в частности пробиотики - бактерийные препараты из живых микроорганизмов, представителей облигатной микрофлоры кишечника - это колибактерин, лактобактерин, бифидумбактерин, бификол и т.д. сухие препараты (1).Widely known are drugs aimed at restoring normal intestinal biocenosis, in particular probiotics - bacterial preparations from living microorganisms, representatives of obligate intestinal microflora - colibacterin, lactobacterin, bifidumbacterin, bificol, etc. dry preparations (1).
Известны также активные биологические добавки на основе живых жидких штаммов бифидо- и лактобактерий, воздействующие как на бифидо-, так и на лактокомпоненты микрофлоры кишечника. В качестве основы используют гидролизат обезжиренного молока, аминный азот, в котором поддерживают не менее 160 мг/%, в качестве кислой составляющей используют аскорбиновую кислоту в количестве 230-250 мг на 1000 мл гидролизата обезжиренного молока.Active biological additives based on live liquid strains of bifidobacteria and lactobacilli are also known, which act on both bifidobacteria and lactic components of intestinal microflora. The base used is a skim milk hydrolyzate, amine nitrogen in which at least 160 mg /% is supported, ascorbic acid in an amount of 230-250 mg per 1000 ml of skim milk hydrolyzate is used as the acidic component.
Биомассы каждого штамма смешивают в соотношении 1:1. Расфасовывают по 2,5-5 мл препарата (2).The biomass of each strain is mixed in a ratio of 1: 1. Packed in 2.5-5 ml of the drug (2).
Известен штамм CG Lactobacillus rhamnosus (ATCC 53/103), обладающий всеми свойствами, присущими данному виду штаммов. Получен из фекалий человека в США S.Sherwood и биохимиком В.Goldin.Known strain CG Lactobacillus rhamnosus (ATCC 53/103), which has all the properties inherent in this type of strain. Obtained from human feces in the USA by S.Sherwood and biochemist B. Goldin.
При применении его при острой диарее данная культура имеет выраженную способность стимулировать иммунный ответ и колонизационную резистентность пищеварительного тракта.When used for acute diarrhea, this culture has a pronounced ability to stimulate the immune response and colonization resistance of the digestive tract.
В задачу исследований входило получить штамм Lactobacillus rhamnosus, предназначенный для непосредственного употребления в пищу и обеспечивающий профилактику и лечение дисбактериоза, нормализацию функций желудочно-кишечного тракта, улучшение обменных процессов, повышение не специфической резистентности организма.The research objective was to obtain a strain of Lactobacillus rhamnosus, intended for direct consumption and providing the prevention and treatment of dysbiosis, the normalization of the functions of the gastrointestinal tract, the improvement of metabolic processes, and the increase in non-specific resistance of the body.
Поставленной задачи нам удалось достичь благодаря тому, что нами выделен штамм из фекалий подростка, идентифицирован во Всероссийской Коллекции Промышленных Микроорганизмов ФГУП ГосНИИИ Генетика по последовательности, кодирующей +63 р РНП, данный штамм отнесен к виду Лактобактерия рамнозус (Lactobacillus rhamnosus), штамм СТ-2-05.We succeeded in achieving this task due to the fact that we isolated a strain from the feces of a teenager, identified in the All-Russian Collection of Industrial Microorganisms of the Federal State Unitary Enterprise State Research Institute of Genetics according to the sequence encoding +63 rnRP, this strain is assigned to the species Lactobacillus rhamnosus (strain Lactobacillus rhamnosus), strain CT-2 -05.
Предложенный штамм обладает следующими свойствами:The proposed strain has the following properties:
МОРФОЛОГИЧЕСКИЕ ПРИЗНАКИ:MORPHOLOGICAL SIGNS:
- Палочки (0,3-0,5)×(1,5-2) мкм, располагаются короткими цепочками или хаотично.- Sticks (0.3-0.5) × (1.5-2) microns, arranged in short chains or randomly.
- Неподвижные споры, капсул не образуют.- Fixed spores, do not form capsules.
- Окраска по Грамму - положительная.- Gram stain is positive.
- Отношение к кислороду - микроаэрофил.- Attitude to oxygen - microaerophile.
- Отношение к рН: пределы (3-7,4), оптимум (5,05±0,5).- Relation to pH: limits (3-7.4), optimum (5.05 ± 0.5).
- Отношение к температуре: термофил, пределы (15-45)°С.- Relation to temperature: thermophile, limits (15-45) ° С.
- Антигенные свойства: Групповой антиген - С.- Antigenic properties: Group antigen - C.
СПОСОБНОСТЬ К СБРАЖИВАНИЮ УГЛЕВОДОВ:ABILITY TO CARBON CARBOHYDRATES:
- Образует при сбраживании L+ молочную кислоту.- Forms with fermentation L + lactic acid.
- Не образует газа из глюкозы.- Does not form gas from glucose.
- Сбраживает галактозу, лактозу, мальтозу, манит, сахарозу, сорбит, фруктозу, глюкозу, рамнозу.- Ferments galactose, lactose, maltose, beckons, sucrose, sorbitol, fructose, glucose, rhamnose.
- Не сбраживает арабинозу, рацинозу, мелибиозу, ксилозу.- Does not ferment arabinose, racinosis, melibiosis, xylose.
- Активность кислотообразования - не менее 120°Т.- The activity of acid formation is not less than 120 ° T.
УСТОЙЧИВОСТЬ К АНТИБИОТИКАМ.RESISTANCE TO ANTIBIOTICS.
- Устойчив к олеандомицину, полимиксину, ристомицину, стрептомицину.- Resistant to oleandomycin, polymyxin, ristomycin, streptomycin.
- Слабо чувствителен к канамицину, неомицину, фузидину.- Weakly sensitive to kanamycin, neomycin, fusidine.
- Предельные ингибирующие концентрации (мкг/мл): гентамицин - 600, левомицетин - 500, мономицин - 600, стрептомицин - 700, полимиксин - 10000, канамицин - 1000, тетрациклин - 450.- Limit inhibitory concentrations (μg / ml): gentamicin - 600, chloramphenicol - 500, monomycin - 600, streptomycin - 700, polymyxin - 10000, kanamycin - 1000, tetracycline - 450.
- Антагонизм: зона подавления роста (мм)- Antagonism: growth inhibition zone (mm)
Sh. Sonnei 5063-19, Sh. Flexneri 170-21, Sh. Flexneri 377, Coli 157-13, St. aureus 209-11, Pr. Vulgaris 177-20, Pr. mirabilis 3177-12.Sh. Sonnei 5063-19, Sh. Flexneri 170-21, Sh. Flexneri 377, Coli 157-13, St. aureus 209-11, Pr. Vulgaris 177-20, Pr. mirabilis 3177-12.
КУЛЬТУРАЛЬНО-МОРФОЛОГИЧЕСКИЕ СВОЙСТВА:CULTURAL-MORPHOLOGICAL PROPERTIES:
- Продукт, синтезируемый штаммом - L+ молочная кислота.- The product synthesized by the strain - L + lactic acid.
- Продуктивность штамма - 2,75% в колбах.- The strain productivity is 2.75% in the flasks.
- Способность определения активности штамма с указанием метода - титрование, среда МРС - 5.- The ability to determine the activity of the strain indicating the method - titration, medium MPC - 5.
- Способ, условия и состав сред для размножения штамма - среда Блаурока или МРС - 5, полужидкая.- The method, conditions and composition of the media for the propagation of the strain - medium Blauroka or MPC - 5, semi-liquid.
Оптимальные условия и состав среды для ферментации - питательная среда на основе гидролизата обезжиренного молока (ГОМ) с добавлением ростовых добавок экстракта дрожжей, глюкозы и солей. Рекомендуемый метод хранения лиофилизированная культура, температура не выше 4°С.The optimal conditions and composition of the medium for fermentation is a nutrient medium based on a skim milk hydrolyzate (HOM) with the addition of growth additives of yeast, glucose and salt extracts. Recommended storage method is lyophilized culture, temperature not higher than 4 ° С.
ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ ШТАММА:GENETIC FEATURES OF THE STRAIN:
- Мутации, делеции, инверсии - нет.- Mutations, deletions, inversions - no.
- Плазмиды - нет.- Plasmids - no.
- Профаги - нет.- Profages - no.
- Прочие генетические особенности - нет.- Other genetic features - no.
- Штамм не является зоопатогенным, фитопатогенным, не представляет опасности.- The strain is not zoopathogenic, phytopathogenic, not dangerous.
Предложенный штамм Lactobacillus rhamnosus CT-2-05 депонирован во Всероссийской Коллекции Промышленных Микроорганизмов ФГУП ГосНИИ Генетика под № В-9072.The proposed strain of Lactobacillus rhamnosus CT-2-05 was deposited in the All-Russian Collection of Industrial Microorganisms of the Federal State Unitary Enterprise State Research Institute of Genetics under No. В-9072.
Штамм используют для получения биологически активной добавки к пище, которая представляет собой биомассу штамма Lactobacillus rhamnosus ВКПМ В-9072, наращенную в питательной среде при следующем соотношении компонентов, об.%:The strain is used to obtain a biologically active food supplement, which is the biomass of the strain Lactobacillus rhamnosus VKPM B-9072, grown in a nutrient medium in the following ratio of components, vol.%:
Активная биологическая добавка названа нами «Биобаланс-В» и выпускается в трех видах: жидкий и сухой в таблетках и капсулах.The active biological supplement we named "Biobalance-B" and is available in three forms: liquid and dry in tablets and capsules.
Приводим конкретные примеры по составу активной биологической добавки:We give specific examples of the composition of an active biological additive:
Пример 1.Example 1
Для производства жидкой биологически активной добавки необходимо применять следующее компоненты, об.%:For the production of liquid biologically active additives it is necessary to apply the following components, vol.%:
Пример 2.Example 2
Для производства капсул необходимо применять следующие компоненты, мас.%:For the production of capsules, it is necessary to use the following components, wt.%:
Пример 3.Example 3
Для производства таблеток применяют следующие компоненты, мас.%:For the production of tablets, the following components are used, wt.%:
В жидком препарате количество живых бактерий равняется 1×107 - 1×108 КОЕ/мл.In a liquid preparation, the number of living bacteria is 1 × 10 7 - 1 × 10 8 CFU / ml.
В таблетках 0,5 г ±10%, содержание живых бактерий - 1×107 - 1×108 КОЕ/г.In tablets, 0.5 g ± 10%, the content of live bacteria is 1 × 10 7 - 1 × 10 8 CFU / g.
В капсулах - 0,12 г ±10% содержится живых бактерий - 1×107 - 1×108 КОЕ/г.In capsules - 0.12 g ± 10% contains live bacteria - 1 × 10 7 - 1 × 10 8 CFU / g.
Предложенная активная биологическая добавка «Биобаланс-В» предназначена для непосредственного употребления в пищу и способствует профилактике и лечению дисбактериоза, нормализации функций желудочно-кишечного тракта, улучшению обменных процессов, повышению неспецифической резистентности организма.The proposed active biological supplement "Biobalance-B" is intended for direct consumption and contributes to the prevention and treatment of dysbiosis, normalization of the functions of the gastrointestinal tract, improve metabolic processes, increase nonspecific resistance of the body.
Предложенная биологически активная добавка апробирована в январе-марте 2005 г. в Московском НИИ педиатрии и детской хирургии с положительным результатом. Задача исследования - оценка клинической эффективности препарата «Биобаланс-В» при коррекции дисбактериоза кишечника у больных с различной патологией ЖКТ.The proposed dietary supplement was tested in January-March 2005 at the Moscow Research Institute of Pediatrics and Pediatric Surgery with a positive result. The objective of the study is to assess the clinical effectiveness of the drug "Biobalance-B" in the correction of intestinal dysbiosis in patients with various gastrointestinal pathologies.
Группу наблюдения составили 25 пациентов. Больные основной группы - 10 человек (5 мальчиков и 5 девочек) получали «Биобаланс-В». В контрольную группу были включены 15 детей (9 мальчиков и 6 девочек) от 3-х до 17 лет с различной патологией ЖКТ и дисбактериозом. Пациенты этой группы получали одно из известных пробиотических средств (пробифор, флорадофилюс, линекс). Лечение обеих групп проводилось 14 дней, дети получали возрастные дозировки. Контрольные исследования проводились через 1 и 2 месяца после окончания лечения.The observation group consisted of 25 patients. Patients of the main group - 10 people (5 boys and 5 girls) received "Bio-balance-B". The control group included 15 children (9 boys and 6 girls) from 3 to 17 years old with various gastrointestinal tract pathologies and dysbiosis. Patients in this group received one of the well-known probiotic agents (probifor, floradofilus, linex). Both groups were treated for 14 days, children received age-related dosages. Control studies were conducted 1 and 2 months after the end of treatment.
Результаты клинических испытаний показали, что «Биобаланс-В» обладает заявленной активностью и имеет высокие пробиотические свойства. Клинический эффект от приема «Биобаланс-В» в некоторых случаях превосходил эффект от приема вышеуказанных пробиотиков, являясь более выраженным и стойким.The results of clinical trials showed that "Biobalance-B" has the declared activity and has high probiotic properties. The clinical effect of taking "Biobalance-B" in some cases exceeded the effect of taking the above probiotics, being more pronounced and persistent.
Предложенная биологическая добавка, обладая высокими пробиотическими, антагонистическими и антибиотическими свойствами данной культуры Lactobacillus rhamnosus ВКПМ В-9072, найдет широкое применение в пищевой промышленности как БАД в качестве профилактического средства, входящего в состав функционального питания для людей, предрасположенных к дисбактериозу; в медицине как биологически активный комплекс, содержащий нормофлору человека для лечения больных с кишечными инфекциями, дисбактериозом и заболеваниями желудочно-кишечного тракта.The proposed biological supplement, possessing the high probiotic, antagonistic and antibiotic properties of this culture of Lactobacillus rhamnosus VKPM B-9072, will be widely used in the food industry as a dietary supplement as a prophylactic that is part of functional nutrition for people predisposed to dysbiosis; in medicine as a biologically active complex containing human normoflora for the treatment of patients with intestinal infections, dysbiosis and diseases of the gastrointestinal tract.
Убедительно просим присвоить предложенной активной биологической добавке название «Биобаланс-В» согласно утвержденной документации.We kindly ask you to assign the name "Bio-balance-B" to the proposed active biological supplement in accordance with the approved documentation.
Источники информацииInformation sources
1. Патент РФ №2192269, А61К 35/74; С12N 1/20, 2002 г.1. RF patent No. 2192269, A61K 35/74; C12N 1/20, 2002
2. Монография Б.А.Шендерова «Медицинская микробная экология и функциональное питание», М.: Грандъ, т.3, 2001 г., с.81.2. The monograph of B. A. Shenderov “Medical microbial ecology and functional nutrition”, Moscow: Grand, vol. 3, 2001, p. 81.
3. Кн. В.А.Княжева. Дисбактериоз. Теория и практика, Нижний Новгород, 1999 г., с.70-73.3. Prince V.A. Knyazheva. Dysbacteriosis Theory and Practice, Nizhny Novgorod, 1999, pp. 70-73.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2005117480/13A RU2302877C2 (en) | 2005-06-07 | 2005-06-07 | Biological food supplement for treatment and prophylaxis of intestine infections complicated with dysbacteriosis and for enhancing nonspecific resistance of organism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2005117480/13A RU2302877C2 (en) | 2005-06-07 | 2005-06-07 | Biological food supplement for treatment and prophylaxis of intestine infections complicated with dysbacteriosis and for enhancing nonspecific resistance of organism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005117480A RU2005117480A (en) | 2006-12-20 |
| RU2302877C2 true RU2302877C2 (en) | 2007-07-20 |
Family
ID=37666475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005117480/13A RU2302877C2 (en) | 2005-06-07 | 2005-06-07 | Biological food supplement for treatment and prophylaxis of intestine infections complicated with dysbacteriosis and for enhancing nonspecific resistance of organism |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2302877C2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2453591C1 (en) * | 2011-04-21 | 2012-06-20 | Общество с ограниченной ответственностью "Бифилюкс" | Strain lactobacillus rhamnosus used for making lactic acid bacillus containing products |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2192269C2 (en) * | 2000-07-03 | 2002-11-10 | Соловьева Ирина Владленовна | Method of preparing curative-prophylactic preparation based on microorganism living strains "lb-complex" |
| RU2206632C2 (en) * | 2001-07-27 | 2003-06-20 | Федеральное Государственное Унитарное Предприятие "Центральный Научно-Исследовательский Институт Конструкционных Материалов "Прометей" | Two-layer corrosion-resistant steel |
| RU2252770C2 (en) * | 2003-09-23 | 2005-05-27 | Одушко Игорь Николаевич | Healthful and dietary product, method for production and uses thereof |
-
2005
- 2005-06-07 RU RU2005117480/13A patent/RU2302877C2/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2192269C2 (en) * | 2000-07-03 | 2002-11-10 | Соловьева Ирина Владленовна | Method of preparing curative-prophylactic preparation based on microorganism living strains "lb-complex" |
| RU2206632C2 (en) * | 2001-07-27 | 2003-06-20 | Федеральное Государственное Унитарное Предприятие "Центральный Научно-Исследовательский Институт Конструкционных Материалов "Прометей" | Two-layer corrosion-resistant steel |
| RU2252770C2 (en) * | 2003-09-23 | 2005-05-27 | Одушко Игорь Николаевич | Healthful and dietary product, method for production and uses thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2453591C1 (en) * | 2011-04-21 | 2012-06-20 | Общество с ограниченной ответственностью "Бифилюкс" | Strain lactobacillus rhamnosus used for making lactic acid bacillus containing products |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005117480A (en) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI417054B (en) | Novel enterococcus faecium ljs-01 and its use for probiotic | |
| RU2439145C2 (en) | Strain of microorganism bacillus smithii tbm112 mscl p737 and its application as food or feed additive, or component of probiotic composition, and probiotic composition | |
| EP0760848A1 (en) | Lactobacillus strains of human origin, their compositions and uses thereof | |
| KR101839374B1 (en) | Bacillus subtilis SCGB 574 strain having antimicrobial activity and probiotics properties and uses thereof | |
| RU2580002C1 (en) | Method of producing autoprobiotic containing living bifidus bacteria and lactic acid bacilli | |
| CN110004072A (en) | One plant of probiotic enterococcus faecalis separation strains A3-1 and its application | |
| KR101839371B1 (en) | Bacillus amyloliquefaciens SRCM 100731 strain having antimicrobial activity and probiotics properties and uses thereof | |
| EP1840205B1 (en) | Bifidobacterium lactis 668 strain used as a component for food products, starters, medicinal and cosmetic agents | |
| KR102434487B1 (en) | Vagina-derived lactobacillus rhamnosus vg.q2 strain having antimicrobial activity against microorganisms causing vaginosis and uses thereof | |
| RU2303058C2 (en) | Agent "biobalans-k" for treatment of intestine infections complicated with dysbacteriosis | |
| KR101839375B1 (en) | Bacillus amyloliquefaciens SRCM 100730 strain having antimicrobial activity and probiotics properties and uses thereof | |
| RU2393214C1 (en) | Immunobiologial antiallergic agent (versions), lactobacillus acidophilus nkjc strain, lactobacillus acidophilus jch strain, lactobacillus acidophilus kaa strain | |
| JP6675703B1 (en) | Lactic acid bacteria, natural immunity activators derived from the lactic acid bacteria, infectious disease preventive / therapeutic agents, and food and drink | |
| KR20220004865A (en) | Lactobacillus brevis SRCM101607 strain having probiotics-related enzyme secretion activity, antioxidant activity, Bile salt hydrolysis, antimicrobial activity, and not producing harmful enzyme and harmful metabolite and uses thereof | |
| RU2302877C2 (en) | Biological food supplement for treatment and prophylaxis of intestine infections complicated with dysbacteriosis and for enhancing nonspecific resistance of organism | |
| RU2298032C2 (en) | Bacillus subtilis 1719 BACTERIUM STRAIN AS PRODUCER OF ANTAGONISTICALLY ACTIVE BIOMASS IN RELATES TO PATHOGENIC MICROORGANISMS, AS WELL AS PROTEOLYTIC, AMYLOLYTIC, AND LIPOLYTIC ENZYMES | |
| RU2491336C1 (en) | Bifidobacterial and lactobacillary consortium for preparing bacterial preparations and dietary supplements for correcting gastrointestinal microflora in individuals of fourteen and older, and method for preparing it, dietary supplement for correcting gastrointestinal microflora in individuals of fourteen and older and bacterial preparation for treating dysbiotic gastrointestinal conditions in individuals of fourteen and older | |
| RU2396968C2 (en) | Agent for treating gastrointestinal disturbances and method for making thereof | |
| RU2373275C1 (en) | Bifidobacterium pseudocatenulatum ov-17 strain, used for making bacterial preparations, bioligically active additives to food, fermented and unfermented food products, hygienic and cosmetic agents | |
| RU2639569C1 (en) | Probiotic bacillus megaterium strain - producer of antibacterial substances, immunomodulators and proteolytic enzymes | |
| KR100720025B1 (en) | Probiotic Lactobacillus and Compositions Comprising the Same | |
| Kumar et al. | Isolation and characterization of endemic strains of Lactobacillus sp. and evaluation of their probiotic activity | |
| RU2151797C1 (en) | Strain lactobacillus acidophilus k/ar-0,8 is resistant to antibiotics and salt-resistant antagonist pathogens of intestine infections | |
| RU2831469C1 (en) | Composition of probiotic agent based on bacterial cultures strains bifidobacterium longum subspecies longum and lacticaseibacillus paracasei subspecies paracasei, intended for therapy and prevention of pathological conditions occurring with underlying disturbed regulation of interactions of "intestine-brain" axis | |
| RU2412239C2 (en) | STRAIN OF Lactobacillus fermentum Z, USED FOR PRODUCTION OF PROBIOTIC CULTURED MILK FOODS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080608 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130608 |
|
| NF4A | Reinstatement of patent |
Effective date: 20141210 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160608 |